Campylobacter

Akeso Biomedical Receives EU Authorization for CI-FER® as a Feed Additive in Piglets

Retrieved on: 
Monday, October 25, 2021
Salmonella, Food safety, Research, Efficiency, Technology, University, Knowledge, Zinc oxide, III, Foodborne illness, European Union, Cementite, Disease, EFSA, Marketing, LLC, Company, Campylobacter, Iron, European Food Safety Authority, Oxidative stress, Professor, CEO, Diarrhea, Escherichia coli, Union, Solution, Health, Acquisition, Mortality, Colon, Gene expression, VIC, Pig, Poultry

BURLINGTON, Ma., Oct. 25, 2021 /PRNewswire-PRWeb/ --Akeso Biomedical, Inc., announced today that the company has obtained authorization in the European Union to market CI-FER as a zootechnical feed additive for piglets and minor porcine species.

Key Points: 
  • BURLINGTON, Ma., Oct. 25, 2021 /PRNewswire-PRWeb/ --Akeso Biomedical, Inc., announced today that the company has obtained authorization in the European Union to market CI-FER as a zootechnical feed additive for piglets and minor porcine species.
  • Akeso Biomedical is a privately held company developing novel, non-antibiotic feed additive technologies to improve gut health and animal performance.
  • CI-FER [iron (III) citrate chelate] for piglets is Akeso's first product for the EU market based on its Fe3C technology.
  • The company conducted five efficacy studies in the EU to demonstrate that piglets receiving CI-FER grew faster, exhibiting higher body weights and better feed efficiency than control piglets.

Veterinary Antibiotics Global Market Report 2021: Anti-parasitic, Anti-bacterial, Non-steroidal anti-inflammatory, Premixes, Injections, Oral Powders, Oral Solutions - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021
Consumer, Health, Pets, Veterinary, Pharmaceutical, Growth, Campylobacter, Bacteria, Food, Zoonosis, Food chain, Extrapyramidal system, Parasitism, Union, Infection, CAGR, Bayer, COVID-19, Federal Food, Drug, and Cosmetic Act, Sale, Human, European Union, Animal, FDA, Boehringer Ingelheim, Salmonella, Pharmaceutical industry, Vaccine, Livestock

The "Veterinary Antibiotics Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Antibiotics Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the veterinary antibiotics market are Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale, Eli Lilly Company and Elanco.
  • The global veterinary antibiotics market is expected to grow from $1.12 billion in 2020 to $1.22 billion in 2021 at a compound annual growth rate (CAGR) of 8.9%.
  • The veterinary antibiotics market consists of sales of veterinary antibiotics and related services.

USDA Food Safety and Inspection Service Chooses 3M for Campylobacter Testing in Poultry

Retrieved on: 
Tuesday, April 20, 2021
Food and drink, Food industry, Articles, Food safety, Food Safety and Inspection Service, Meat inspection, Campylobacter, 3M, Foodborne illness

PAUL, Minn., April 20, 2021 /PRNewswire/ -- 3M Food Safety has been awarded a contract from the U.S. Department of Agriculture Food Safety and Inspection Service (USDA FSIS) for Campylobacter1 detection with the 3M Molecular Detection System.

Key Points: 
  • PAUL, Minn., April 20, 2021 /PRNewswire/ -- 3M Food Safety has been awarded a contract from the U.S. Department of Agriculture Food Safety and Inspection Service (USDA FSIS) for Campylobacter1 detection with the 3M Molecular Detection System.
  • The award makes the 3M Molecular Detection System the primary method to be used by USDA FSIS for the detection of Campylobacter in poultry.
  • To read more about poultry pathogen testing data, access a copy of the whitepaper at www.3M.com/PoultryPathogens .\n"The 3M Molecular Detection System has proven to be a highly accurate and efficient tool for many food producers and contract labs globally," said Srini Raman, 3M Food Safety vice president.\nThe 3M Molecular Detection System makes molecular detection of foodborne pathogens simpler and faster.
  • 3M and the 3M logo are the worldwide trademarks or registered trademarks of 3M.

Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay

Retrieved on: 
Thursday, April 1, 2021
Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Meridian Bioscience, Immunologic tests, Epsilonproteobacteria, Assay, Lateral flow test, Campylobacter

CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Companys new Curian Campy assay.

Key Points: 
  • CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Companys new Curian Campy assay.
  • This assay is one of many assays in the pipeline that expands the Curian menu, continuing Meridians leadership in the gastrointestinal disease and lateral flow testing market.
  • Curian Campy, for use with the Curian Analyzer, is a rapid, qualitative fluorescent immunoassay for the detection of Campylobacter spp.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Campylobacter and Salmonella cases stable in EU

Retrieved on: 
Friday, February 26, 2021
Medical specialties, Infectious diseases, Bacterial diseases, Bacteriology, Zoonoses, Listeriosis, Salmonellosis, Campylobacter, Salmonella, Zoonosis

Campylobacteriosis, which has been the most reported gastrointestinal disease in EU since 2005, affected more than 220,000 people in 2019.

Key Points: 
  • Campylobacteriosis, which has been the most reported gastrointestinal disease in EU since 2005, affected more than 220,000 people in 2019.
  • Salmonellosis was the second most reported zoonotic disease in the EU, affecting about 88,000 people.
  • Of the 66,113 samples of ready-to-eat foods foods that do not need to be cooked prior consumption 0.3% tested positive for Salmonella.
  • The trend of confirmed human cases of listeriosis was stable in 2015-2019, after a long period of increase.

Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform

Retrieved on: 
Wednesday, January 27, 2021
Epsilonproteobacteria, Medical specialties, Bacteria, Clinical medicine, Intestinal infectious diseases, Diarrhea, Feces, Sanitation, bioRxiv, Preprint, Campylobacter, Spirulina

The CARB-X project will develop anantibiotic-alternative that targets two key pathogens behind the diarrheal diseases that kill thousands of infants and children in the developing world: Campylobacter jejuniand enterotoxigenicE.

Key Points: 
  • The CARB-X project will develop anantibiotic-alternative that targets two key pathogens behind the diarrheal diseases that kill thousands of infants and children in the developing world: Campylobacter jejuniand enterotoxigenicE.
  • Pending peer-review, the research titled "Expression and Manufacturing of Protein Therapeutics in Spirulina" has been posted on the online preprint server bioRxiv .
  • We are grateful for the support from CARB-X to help advance our approach for diarrheal diseases."
  • Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for several prevalent, worldwide diseasesmany of which currently lack any effective treatments.

US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic

Retrieved on: 
Monday, July 20, 2020
Bacteria, Epsilonproteobacteria, Organisms, Microorganisms, Drug Safety, Food and Drug Administration, Escherichia coli, ETEC, Campylobacter, Investigational New Drug

The FDA were recently provided a Pre- Investigational New Drug (IND) package for the new Hyper-immune therapeutic which specifically targets Campylobacter jejuni capsule and Enterotoxigenic Escherichia coli (ETEC) colonization factor antigen 1.

Key Points: 
  • The FDA were recently provided a Pre- Investigational New Drug (IND) package for the new Hyper-immune therapeutic which specifically targets Campylobacter jejuni capsule and Enterotoxigenic Escherichia coli (ETEC) colonization factor antigen 1.
  • Following FDA review the agency provided a written response to the non-clinical questions posed in the briefing documentation as well as providing additional guidance and comments to support the planned IND submission.
  • This is an important milestone in the development of any new drug for therapeutic evaluation.
  • The company is also please to inform shareholders that the manufacturing program is proceeding as planned.

Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense

Retrieved on: 
Friday, June 19, 2020
Bacteria, Organisms, Articles, Biotechnology, Breastfeeding, Colostrum, Escherichia coli, ETEC, CSIRO, Vaccine, Campylobacter

Immuron has now executed a research agreement with Australias national science agency, CSIRO.

Key Points: 
  • Immuron has now executed a research agreement with Australias national science agency, CSIRO.
  • to produce the new therapeutic against Campylobacter and Entero-Toxigenic Escherichia coli (ETEC) for clinical evaluation by the US Department of Defense.
  • Under the terms of the research agreement CSIRO has been engaged to produce a hyper-immune bovine colostrum product using vaccines developed by the NMRC.
  • The work will be conducted at the Department of Agriculture and Water Resources Biosecurity Approved Arrangement facilities located in Armidale NSW.

2020 Global Campylobacter Diagnostics Market - Hospitals, Commercial/Private Labs, Physician Offices & Public Health Labs - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 30, 2020
Health, Other Health, Epsilonproteobacteria, Campylobacter, Capnophiles, Market segmentation, Epidemiology

The report presents a detailed analysis of the Campylobacter diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.

Key Points: 
  • The report presents a detailed analysis of the Campylobacter diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.
  • Current scientific views on the Campylobacter definition, epidemiology and etiology are reviewed.
  • The report provides the 5-year test volume and sales forecasts by country for the following market segments:

2020 Europe Enteric Disease testing Market: Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio & Yersinia - ResearchAndMarkets.com

Retrieved on: 
Monday, January 27, 2020
Infectious diseases, Biotechnology, Health, Medical specialties, Infectious diseases, Medicine, Neglected diseases, Tropical diseases, Pathogenic bacteria, Campylobacter, Capnophiles, Epsilonproteobacteria, Enterovirus, Escherichia coli, Rotavirus

This new 363-page report from the author provides analysis of the European enteric disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.

Key Points: 
  • This new 363-page report from the author provides analysis of the European enteric disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
  • This report presents detailed analysis of the Enteric Disease market in Europe (France, Germany, Italy, Spain, UK).
  • Current scientific views on epidemiology and etiology are presented for Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio and Yersinia.
  • The report provides test volume and sales forecasts and market segment, including:
    In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of enteric disease diagnostic products, by test and country.